Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/222858
Title: RNU6-1 in circulating exosomes differentiates GBM from non-neoplastic brain lesions and PCNSL but not from brain metastases
Author: Puigdelloses Vallcorba, Montserrat
González Huarriz, Marisol
García Moure, Marc
Martínez Vélez, Naiara
Esparragosa Vázquez, Inés
Bruna, Jordi
Zandio, Beatriz
Agirre, Amaia
Marigil, Miguel
Petrirena, Gregorio
Núñez Córdoba, Jorge M.
Tejada Solís, Sonia
Díez Valle, Ricardo
Gállego Culleré, Jaime
Martínez Vila, Eduardo
Patiño García, Ana
Alonso, Marta M.
Gállego Pérez larraya, Jaime
Keywords: Tumors cerebrals
Metàstasi
Marcadors tumorals
Brain tumors
Metastasis
Tumor markers
Issue Date: 31-Jan-2020
Publisher: Oxford University Press (OUP)
Abstract: Background. Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Circulating biomarkers may assist in the processes of differential diagnosis and response assessment. GBM cells release extracellular vesicles containing a subset of proteins and nucleic acids. We previously demonstrated that exosomes isolated from the serum of GBM patients had an increased expression of RNU6-1 compared to healthy subjects. In this exploratory study, we investigated the role of this small noncoding RNA as a diagnostic biomarker for GBM versus other brain lesions with some potential radiological similarities. Methods. We analyzed the expression of RNU6-1 in circulating exosomes of GBM patients (n = 18), healthy controls (n = 30), and patients with subacute stroke (n = 30), acute/subacute hemorrhage (n = 30), acute demyelinatinglesions (n = 18), brain metastases (n = 21), and primary central nervous system lymphoma (PCNSL; n = 12) using digital droplet PCR. Results. Expression of RNU6-1 was significantly higher in GBM patients than in healthy controls (P = .002).RNU6-1 levels were also significantly higher in exosomes from GBM patients than from patients with nonneoplastic lesions (stroke [P = .05], hemorrhage [P = .01], demyelinating lesions [P = .019]) and PCNSL (P = .004).In contrast, no significant differences were found between patients with GBM and brain metastases (P = .573).Receiver operator characteristic curve analyses supported the role of this biomarker in differentiating GBM from
Note: Reproducció del document publicat a: https://doi.org/10.1093/noajnl/vdaa010
It is part of: Neuro-Oncology Advances, 2020, vol. 2, num. 1
URI: https://hdl.handle.net/2445/222858
Related resource: https://doi.org/10.1093/noajnl/vdaa010
ISSN: 2632-2498
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
RNU6-1 in circulating exosomes different.pdf604.71 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons